Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.72 USD

11.72
3,700,058

-0.08 (-0.68%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $11.71 -0.01 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates

Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Iovance (IOVA) Might Surprise This Earnings Season

Iovance (IOVA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi

The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.

Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance

Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy for Stellar Returns

Universal Stainless & Alloy Products (USAP), Lakeland Industries (LAKE), NGL Energy Partners (NGL) and Iovance Biotherapeutics (IOVA) have been selected as the breakout stocks for today.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Company News for Dec 28, 2023

Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA

Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates

Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug

Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.

Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2

Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 41.98% and 96.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug

Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.

Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study

Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.

Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.